Abstracts Archive - Page 1093 of 2425 - ACR Meeting Abstracts

Abstract Number: 1326 • 2018 ACR/ARHP Annual Meeting
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
Serdal Ugurlu¹, Oguzhan Selvi², Bilgesu Ergezen¹ and Huri Ozdogan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…
Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
Haiting Wang¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye², ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
Abstract Number: 1328 • 2018 ACR/ARHP Annual Meeting
Recurrent Pericarditis: A Challenge in Autoinflammatory Disease Clinic and the Role of Anakinra
Blas Betancourt¹, Amanda Ombrello², Ananta Subedi³, Patrycja M. Hoffmann² and Daniel L. Kastner⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²NHGRI, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, NIAMS, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Recurrent pericarditis is a common complication following an acute episode of pericarditis affecting about 15-30% of the cases. The etiology of this condition is…
Abstract Number: 1329 • 2018 ACR/ARHP Annual Meeting
Combination of Methotrexate and Leflunomide in Refractory Chronic Adult Onset Still’s Disease: Case Series and Literature Review
Eunyoung Emily Lee and Jin Kyun Park, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To demonstrate the efficacy of methotrexate (MTX) and leflunomide (LEF) combination therapy in refractory chronic adult onset Still¡¯s disease (AOSD). Methods: This is a…
Abstract Number: 1330 • 2018 ACR/ARHP Annual Meeting
Dyskeratotic Cells in Persistent Pruritic Skin Lesions Are Apoptotic and Associated with High Levels of Serum IL-18, and Possibly Predict the Outcomes in Adult-Onset Still’s Disease
Hirofumi Nishikawa¹, Yoshinori Taniguchi¹, Natsuki Maeda¹, Satoshi Inotani¹, Kimiko Nakajima², Kaoru Arii³ and Yoshio Terada¹, ¹Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Nankoku, Japan, ²Dermatology, Kochi Medical School, Nankoku, Japan, ³Internal Medicine, Kochi Red Cross Hospital, Kochi, Japan
Background/Purpose: To assess the clinical significance of dyskeratotic cells (DCs) in skin lesions of adult-onset Still’s disease (AOSD). Methods: We assessed clinical characteristics, serum markers,…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…
Abstract Number: 1332 • 2018 ACR/ARHP Annual Meeting
Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
Hanna Kim¹, Angelique Biancotto², Foo Cheung², Terrance P. O'Hanlon³, Yan Huang⁴, Frederick W. Miller³, Raphaela Goldbach-Mansky⁴ and Lisa G. Rider⁵, ¹Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a complex heterogeneous autoimmune disease. To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum…
Abstract Number: 1333 • 2018 ACR/ARHP Annual Meeting
Abnormal Function of High Density Lipoproteins in Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Jennifer Wang¹, Ani Shahbazian¹, Buzand Oganesian², Ilana Golub¹, Srinivasa T. Reddy¹ and Christina Charles-Schoeman³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los angeles, CA, ³Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Damage to the vascular endothelium is strongly implicated in the pathogenesis of dermatomyositis (DM) and to a lesser degree other idiopathic inflammatory myopathies (IIM).…
Abstract Number: 1334 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies
Jiram Torres-Ruíz¹, Araceli Leal-Alanis², Ricardo Vazquez-Rodriguez³, Mario René Alvarado-Lara³, Edgar Rafael Carazo-Vargas³, José Luis Maravillas-Montero⁴, Jorge Alcocer-Varela⁵ and Diana Gómez-Martín⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁴Red de Apoyo a la Investigación, UNAM, Mexico, Mexico, ⁵Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Low density granulocytes (LDGs) are a subset of neutrophils that spontaneously produce neutrophil extracellular traps (NETs) and type I IFN. The latter correlates with…
Abstract Number: 1335 • 2018 ACR/ARHP Annual Meeting
Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Krisha Desai^1,2, Majid Zeidi^3,4, Ming-Lin Liu^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EVs) are micron-scale bilayer membrane vesicles released from almost all cell types under activation or apoptosis. They have been detected in various…
Abstract Number: 1336 • 2018 ACR/ARHP Annual Meeting
Functional, Radiographic and Serologic Correlates of Anti-SSA52 Kd – Associated Interstitial Lung Disease
Estefania Calle Botero¹, Benjamin Wang², Juan J Maya², Isabel Mira-Avendano³ and Andy Abril², ¹Rheumatology, Universidad de Antioquia, Medellin, Colombia, ²Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ³Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Autoantibodies against the SSA52 Kd protein (anti-SSA52) have been cataloged as myositis-associated antibodies, occurring in up to 30% of cases idiopathic inflammatory myopathies (IIM),…
Abstract Number: 1337 • 2018 ACR/ARHP Annual Meeting
Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis
Harunobu Iida¹, Hironari Hanaoka¹, Kana Ishimori², Tomofumi Kiyokawa¹, Yukiko Takakuwa¹ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Clinically amyopathic dermatomyositis (CADM) patients are frequently manifested by rapidly progressive interstitial lung disease (ILD) and associated with a poor prognosis. Recently cardiac involvement…
Abstract Number: 1338 • 2018 ACR/ARHP Annual Meeting
Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
Angelika Lackner¹, Viktoria Tiefenthaler², Jalia Mirzayeva², Winfried Graninger³ and Martin Stradner⁴, ¹Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Department of Rheumatology & Immunology, Medical University of Graz, Graz, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Validation of the diagnostic accuracy of myositis-related antibodies in a large patient-cohortLackner, A; Tiefenthaler, V; Mirzayeva, J; Graninger, W; Stradner, MH Background/Purpose: Myositis-specific antibodies (MSA) and…
Abstract Number: 1339 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Per-Johan Jakobsson^2,4, Susanne Graslund^1,2,3 and Ingrid E. Lundberg^1,2, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune myositis (rheumatic muscle inflammation) associated with interstitial lung disease (ILD) and arthritis is strongly correlated with the presence of anti-histidyl tRNA synthetase (HisRS)…
Abstract Number: 1340 • 2018 ACR/ARHP Annual Meeting
Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome
Tsuneo Sasai¹, Ran Nakashima², Yuki Ishikawa³, Takuya Isayama⁴ and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ⁴Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl-tRNA-synthetase (ARS) antibodies are myositis specific autoantibodies and associated with common clinical characteristics called anti-synthetase syndrome (ASS). Recently anti-ARS detecting enzyme-linked immunosorbent assay (ELISA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].